<DOC>
	<DOCNO>NCT01228227</DOCNO>
	<brief_summary>An increase cardiac biomarkers show occur 5 % 30 % patient otherwise successful percutaneous coronary intervention ( PCIs ) ( 1 ) Apart side-branch occlusion , intimal dissection coronary spasm , possible aetiology myonecrosis PCI might distal embolization atherogenic material plaque disruption , ( 2 ) cause obstruction blood flow capillary level result micro-infarction . ( 3,4 ) Recent study suggest pretreatment Atorvastatin may associate reduction infarct size elective PCI . ( 5-7 ) . Actually standard pretreatment patient undergoing elective coronary-PCI already treat aspirin clopidogrel load dose administration procedure . ( 8,9 ) The investigator compare high ( 80mg ) re-loading dose Atorvastatin high load dose Rosuvastatin ( 40 mg ) administer within 24h procedure reduce rate periprocedural MI . Therefore , investigator conduct single center , prospective randomize study ass whether single , high ( 80mg ) loading ( within 24h ) dose Atorvastatin compare single load dose Rosuvastatin ( 20 mg ) effective prevent elevation biomarkers MI elective coronary stent implantation . We evaluate incidence MACCE ( occur cardiac death , myocardial infarction ( include periprocedural myonecrosis ) stroke 30 day 6 12 month follow-up .</brief_summary>
	<brief_title>ROsuvastatin Pretreatment Reduce MyocArdial Periprocedural Necrosis : Comparison With Atorvastatin Reloading</brief_title>
	<detailed_description />
	<mesh_term>Necrosis</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<criteria>Patients stable angina Baseline myocardial enzyme rise</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Myonecrosis</keyword>
	<keyword>Percutaneous Angioplasty</keyword>
	<keyword>Myocardial Infarction</keyword>
</DOC>